Synthesis and Antitumor Activities of Aquayamycin and Analogues Of

Total Page:16

File Type:pdf, Size:1020Kb

Synthesis and Antitumor Activities of Aquayamycin and Analogues Of A Dissertation entitled Synthesis and Antitumor Activities of Aquayamycin and Analogues of Derhodinosylurdamycin A and Synthesis of S-Linked Trisaccharide Glycal of Derhodinosylurdamycin A by Padam Prasad Acharya Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Chemistry ___________________________________________ Dr. Jianglong Zhu, Committee Chair ___________________________________________ Dr. Steven J. Sucheck, Committee Member ___________________________________________ Dr. Peter R. Andreana, Committee Member ___________________________________________ Dr. L. M. Viranga Tillekeratne, Committee Member ___________________________________________ Dr. Cyndee Gruden, Dean College of Graduate Studies The University of Toledo August 2019 © 2019 Padam Prasad Acharya This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Synthesis and Antitumor Activities of Aquayamycin and Analogues of Derhodinosylurdamycin A and Synthesis of S-Linked Trisaccharide Glycal of Derhodinosylurdamycin A by Padam Prasad Acharya Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Chemistry The University of Toledo August 2019 Angucycline natural antibiotics are one class of bioactive natural products which contain a tetracyclic ring frame assembled in an angular manner and are diversely glycosylated. These rapidly growing natural products exhibit diverse biological activities including enzymatic inhibitions, antitumor activities, antimicrobial activities, and platelet aggregation inhibition. The urdamycins are a subclass of angucyclines natural products and were first detected during the chemical screening of secondary metabolites produced by Streptomyces fradiae by Drautz and Co-workers in 1986. They are structurally related with an aquayamycin type of angucycline natural products which contains a C- glycosylated benz[a]anthraquinone core and a cis-diol at the ring junction. Urdamycins are bioactive natural products but the mode of action is unknown, therefore it would be appealing to prepare aquayamycin and analogs of derhodinosylurdamycin A for extensive SAR studies. Recently, we have completed the total syntheses of aquayamycin and analogues of derhodinosylurdamycin A with and without 2-deoxy sugar subunits. The synthesis was carried out on the basis of the convergent synthesis of derhodinosylurdamycin A as previously reported from our group. The mild cationic gold- iii catalyzed glycosylation with S-but-3-ynyl thioglycoside donors was employed for the synthesis of analogues bearing disaccharide subunits containing α-L-olivoside and α-L- olioside moiety, respectively. After the syntheses of these natural and unnatural compounds, we submitted aquayamycin, four different analogues, and our previously synthesized derhodinosylurdamycin A to the Development Therapeutics Program of the National Cancer Institute of National Institutes of Health for the NCI-60 Human Tumor Cell Lines Screening using standard protocols. It was found that the analogue bearing no sugar subunit demonstrates good potential for growth inhibition and cytotoxic activity against a variety of human cancer cell lines, however, aquayamycin, derhodinosylurdamycin A, and three other analogues bearing sugar subunits did not show significant antiproliferative activity against those human cancer cell lines. Thus we concluded that the sugar is not helpful to improve the anticancer activity of aquayamycin type of angucycline natural products. Derhodinosylurdamycin A, a bioactive natural product was discovered in 1989 by Zeeck et al., which was later found as the main urdamycin metabolite from S. fradiae Tü2717 mutant lacking UrdGT1a. Dehodinosylurdamycin A exhibits cytotoxic activity against L1210 leukemia cell lines (IC50 = 0.75 μg/mL). Structurally, it consists of tetracyclic aglycon core and a trisaccharide subunit connected via β-C-aryl glycosidic linkage. This trisaccharide subunit is composed of deoxy sugar subunits including two D- olivose and one L-rhodinose. Deoxy sugars are the important constituents of bioactive natural products, however, stereoselective synthesis of 2-deoxyglycosides remains a challenge due to lack of directing group at C2 position and are susceptible towards hydrolysis. Carbohydrate mimics such as S-linked glycosides are known to be resistant iv towards enzyme or acid-mediated hydrolysis. Therefore it is appealing to synthesize S- linked 2-deoxyglycosides. We successfully achieved the stereoselective synthesis of S- linked trisaccharide glycal of antitumor antibiotic derhodinosylurdamycin A. This synthesis was accomplished based on our group previously developed umpolung S- glycosylation strategy which utilizes the glycosyl lithium species for streoselective sulfenylation. We also found out that an alkyl thiocyanate is better electrophile than corresponding asymmetric disulfide for stereoselective sulfenylation of 2-deoxy glcosyl lithium. v This work is dedicated to my parents Mr. Tanka Prasad Acharya and Mrs. Nyaya Kumari Acharya. vi Acknowledgements My sincere gratitude goes to my advisor, Prof. Dr. Jianglong Zhu, for his sanguine support and constructive guidance since my first day in a laboratory. I sincerely appreciate his worthy of imitation training and encouragement that helped me to develop the proper skill required to conduct research. This attainment wouldn’t have been possible without his direction. I am grateful to the members of my research committee Prof. Dr. Steven J. Sucheck, Prof. Dr. Peter R. Andreana and Asso. Prof. Dr. L.M. Viranga Tillekeratne for their intuitive comments and valuable suggestions during my study. My thanks go to an undergraduate Sandip Janda whose hard work helped me to accomplish my project on time. I would also like to thank Dr. Kim for NMR and MS assistance. My previous and current lab members are the characters of admiration, the discussion with them was always fruitful. I thank the Department of Chemistry and Biochemistry, the University of Toledo for this opportunity. I would also like to appreciate NSF (CHE-1213352 and CHE-1464787) for partially funding my projects. My thanks also go to my parents and family members for their moral and emotional support so far. At last but not least, I am thankful to my wife Jiwan for her relentless support, care, and love throughout. vii Table of Contents Abstract .............................................................................................................................. iii Acknowledgements ........................................................................................................... vii Table of Contents ............................................................................................................. viii List of Schemes .................................................................................................................. ix List of Tables ..................................................................................................................... xi List of Figures ................................................................................................................... xii List of Abbreviations ....................................................................................................... xiii Chapter 1 Synthesis and Antitumor Activities of Aquayamycin and Analogues of Derhodinosylurdamycin A 1.1 Background and Significance ...............................................................................1 1.1.1 Introduction of angucycline natural products ..............................................1 1.1.2 Urdamycin natural products .........................................................................3 1.1.3 Biological activities and mode of action of urdamycin natural products ....5 1.1.4 Earlier syntheses of aquayamycin type natural products .............................6 1.1.5 Analogues designed ...................................................................................10 1.2 Results and Discussion .........................................................................................10 1.2.1 Synthetic strategy .......................................................................................10 1.2.2 Synthesis of tetracyclic aryliodide .............................................................12 1.2.2.1 Synthesis of enantiopure epoxide and vinyl bromide ..........................12 viii 1.2.2.2 Synthesis of enone .........................................................................13 1.2.2.3 Synthesis of cyanophthalide ..........................................................14 1.2.2.4 Synthesis of tetracyclic aryliodide ......................................................15 1.2.3 Synthesis of aquayamycin..........................................................................16 1.2.3.1 Synthesis of glycal stannane ..........................................................16 1.2.3.2 Synthesis of aquayamycin..............................................................17 1.2.4 Synthesis of analogue A.............................................................................19 1.2.5 Synthesis of analogue B .............................................................................19 1.2.5.1 Synthesis of D-fucal derived glycal stannane ................................19 1.2.5.2 Synthesis of analogue B .................................................................20
Recommended publications
  • Chemical Studies on Antibiotics and Other Hioactive Microbial Products by Prof
    HETEROCYCLES, Yo1 13, 1979 CHEMICAL STUDIES ON ANTIBIOTICS AND OTHER HIOACTIVE MICROBIAL PRODUCTS BY PROF. HAMA0 UMEZAWA Kenji Mg&* and Mzseii oggg** *Institute of Microbial Chemistrv, 14-23 Kamiosaki 3-Chome, Shinagawa-ku, Tokyo 141, and **Faculty of Pharmaceutical Sci- ences, University of Tokyo, ~unkyo-ku,~okvo 113, Japan AS written briefly by Dr. Umezawa himself in the preface of this book, the study of antibiotics in Japan was started in the beginning of 1944 in order to produce penicillin. In September of 1944, the first penicillin in Japan was extracted from culture filtrates of Penicillium Y-176 cultured in Erlenmeyer flasks placed on his table. This strain was selected from the strains supplied by the late Dr. Teijiro Yabuta to Dr. Umezawa on the basis of its activitv to inhibit the growth of Staphlococci but not E. coli and its formation of a golden pigment in its cul- tured broth. At that time, there was no laboratory equipped with a cold incubator for a 25OC culture in Tokyo. Dr. Umezawa was at that time in the Institute of In- fectious Disease of the University of Tokyo (at present called Institute of Medi- cal Sciences of the University of Tokyo). Fortunately this institute was not bombed during the last world war, but all Japanese researchers suffered from the shortage of glasswares, reagents, equipments and foreign journals. Moreover, no Japanese journals were published from about 1944 to 1948. Japanese Antibiotic Re- search Association (at that time called Japanese Penicillin Research Association) was established in August of 1946 and held monthly meetings for the presentation of papers since September of 1946.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0243873 A1 Aversa Et Al
    US 20130243873A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0243873 A1 AVersa et al. (43) Pub. Date: Sep. 19, 2013 (54) MMUNOMODULATORY COMPOSITIONS Publication Classification (75) Inventors: Vincenzo Aversa, Ridgewood Swords (51) Int. C. (IE); Ivan Coulter, Mount Merrion (IE): A638/3 (2006.01) Mónica Torres Rosa, Dublin (IE): A619/16 (2006.01) Bernard Francis McDonald, A613 L/502 (2006.01) Castleblayney (IE) (52) U.S. C. CPC ............... A61K 38/13 (2013.01); A61 K3I/502 (73) Assignee: Sigmoid Pharma Limited, Dublin (IE) (2013.01); A61 K9/16 (2013.01); A61K 9/167 (2013.01) (21) Appl. No.: 13/989,372 USPC ......... 424/495; 424/278.1; 424/499: 424/490 (22) PCT Fled: Nov. 25, 2011 (86) PCT NO.: PCT/EP2011/071088 (57) ABSTRACT S371 (c)(1), (2), (4) Date: May 23, 2013 Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxy (30) Foreign Application Priority Data lase inhibitor and/or an immunosuppressant. Exemplary for mulations comprise hydralazine as a hydroxylase inhibitor Nov. 25, 2010 (GB) ................................... 102OO32.7 and/or cyclosporin A as an immunosuppressant. Patent Application Publication Sep. 19, 2013 Sheet 1 of 23 US 2013/0243873 A1 105 - 100 95 - 90 - -- No DSS -- DSS 2.5% ... DSS - A 85 - DSS - B -- DSS - C 80 O 1 2 3 4 5 6 Figure 1 10 9 -(e-NO DSS 8 on to DSS 2.5% 7 Yori:WWWW DSS -- A DSS - B 6 -ie- DSS - C 5 4 3 2 1 O Figure 2 Patent Application Publication Sep.
    [Show full text]
  • Investigations of Novel Mechanisms of Action for Anti-Bacterial and Anti-Cancer Agent Development
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2014 Investigations of Novel Mechanisms of Action for Anti-Bacterial and Anti-Cancer Agent Development Jenson Verghese Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/611 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Jenson Verghese 2014 All Rights Reserved INVESTIGATIONS OF NOVEL MECHANISMS OF ACTION FOR ANTI-BACTERIAL AND ANTI-CANCER AGENT DEVELOPMENT A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. by JENSON VERGHESE Masters in Science, Virginia Commonwealth University, Richmond, V.A, U.S.A, 2009 Director: KEITH C. ELLIS ASSISTANT PROFESSOR, DEPARTMENT OF MEDICINAL CHEMISTRY Virginia Commonwealth University Richmond, Virginia May 2014 Acknowledgement First and foremost, I would like to thank my wife: Anu and my family for all the support they provided while I was preparing this work. The last few months in school was exhaustive and torturous and I would not have made it through, if it was not for their unending support and encouragement. I would like to thank my advisor and mentor Dr. Keith C. Ellis for the support and knowledge he has given me throughout the past five years.
    [Show full text]
  • Download Article (PDF)
    CHEMISTRY OF ENZYME INHffiiTORS OF MICROBIAL ORIGIN HAMAO UMEZAWA Institute of Microbial Chemistry and Department of Antibiotics, National Institute of Health, Tokyo, Japan ABSTRACT Study of antibiotics has furnished interesting materials to chemistry of natural products. I initiated the screening study of enzyme inhibitors produced by microorganisms and isolated Ieupeptin and antipain inhibiting trypsin and papain, chymostatin inhibiting chymotrypsin, pepstatin inhibiting pepsin, panosialin inhibiting sialidases, oudenone inhibiting tyrosine hydroxylase, dopastin inhibiting dopamine ß-hydroxylase, aquayamycin and chrothiomycin inhibiting tyrosine hydroxylase and dopamine ß-hydroxylase. Structures and syntheses ofmost ofthese compounds have been studied. I also found dopamine ß-hydroxylase-inhibiting activity of fusaric acid and oosponol, and xanthine­ oxidase inhibiting activity of 5-formyluracil which were produced by micro­ organisms. Chemical study of enzyme inhibitors has given useful information on the structurejactivity relation. The effect of pepstatin on stomach ulcer, and the hypotensive effect of oudenone and fusaric acid have been observed clinically. Enzyme inhibitors produced by microorganisms are the most valuable new area extended from antibiotics and will furnish new materials interesting in chemistry. biosynthesis, pharmacology, and utility. Research on antibiotics has contributed to the chemistry of natural products, furnishing materials of interesting structures, chemical syntheses, biosyntheses and of interesting
    [Show full text]
  • The Role of Protein Posttranslational Modifications in Cellular
    SAGE-Hindawi Access to Research Journal of Amino Acids Volume 2011, Article ID 207691, 13 pages doi:10.4061/2011/207691 Review Article Small Changes Huge Impact: The Role of Protein Posttranslational Modifications in Cellular Homeostasis and Disease Tejaswita M. Karve 1 and Amrita K. Cheema2 1 Department of Biochemistry, Cellular & Molecular Biology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, 3900 Reservoir Road, NW, Washington DC 20057, USA 2 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA Correspondence should be addressed to Amrita K. Cheema, [email protected] Received 23 February 2011; Accepted 18 April 2011 Academic Editor: Zulfiqar Ahmad Copyright © 2011 T. M. Karve and A. K. Cheema. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Posttranslational modifications (PTMs) modulate protein function in most eukaryotes and have a ubiquitous role in diverse range of cellular functions. Identification, characterization, and mapping of these modifications to specific amino acid residues on proteins are critical towards understanding their functional significance in a biological context. The interpretation of proteome data obtained from the high-throughput methods cannot be deciphered unambiguously without a priori knowledge of protein modifications. An in-depth understanding of protein PTMs is important not only for gaining a perception of a wide array of cellular functions but also towards developing drug therapies for many life-threatening diseases like cancer and neurodegenerative disorders. Many of the protein modifications like ubiquitination play a decisive role in various drug response(s) and eventually in disease prognosis.
    [Show full text]
  • Natural Compounds As Antimicrobial Agents
    Natural Compounds as Antimicrobial Agents • Carlos M. and Franco Beatriz Vázquez Belda Natural Compounds as Antimicrobial Agents Edited by Carlos M. Franco and Beatriz Vázquez Belda Printed Edition of the Special Issue Published in Antibiotics www.mdpi.com/journal/antibiotics Natural Compounds as Antimicrobial Agents Natural Compounds as Antimicrobial Agents Special Issue Editors Carlos M. Franco Beatriz V´azquezBelda MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Special Issue Editors Carlos M. Franco Beatriz V´azquez Belda University of Santiago de Compostela University of Santiago de Compostela Spain Spain Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Antibiotics (ISSN 2079-6382) (available at: https://www.mdpi.com/journal/antibiotics/special issues/natural compounds agents). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03936-048-2 (Hbk) ISBN 978-3-03936-049-9 (PDF) Cover image courtesy of Gang Pan. c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND.
    [Show full text]
  • Isolation and Structure Elucidation of New Fridamycin Type
    VOL. 56 NO. 11, NOV. 2003 THE JOURNAL OF ANTIBIOTICS pp. 942-949 Himalomycin A and B: Isolation and Structure Elucidation of New Fridamycin Type Antibiotics from a Marine Streptomyces Isolate† RAJENDRA P. MASKEYa, ELISABETH HELMKEb and HARTMUT LAATSCHa,* aDepartment of Organic Chemistry, University of Gottingen, Tammannstrasse 2, Gottingen D-37077, Germany bAlfred-Wegner-Institute for Polar and Marine Research, Am Handelshafen 12, Bremerhaven D-27570, Germany (Received for publication July 7, 2003) In our screening of marine Streptomycetes for bioactive compounds, in addition to the known metabolites rabelomycin (1), fridamycin D (2b), N-benzylacetamide and N-(2'- phenylethyl) acetamide, two new anthracycline antibiotics designated as himalomycin A (2c) and B (2d) were isolated from the culture broth of the marine Streptomyces sp. isolate B6921. The structure of the new antibiotics was determined by comparison of the NMR data with those of fridamycin D (2b) and by detailed interpretation of mass, 1D and 2D NMR spectra. Among the more than 45 angucycline antibiotics, less brown to grey with anisaldehyde/sulphuric acid and than 10 are C glycosides. Biogenetically related with these deserved further interest. The colour change from orange to tetracyclic quinones is a small group of antibiotics red on treatment with diluted sodium hydroxide indicated consisting of fridamycins A, B, D (2b) and E1,2), them to contain the peri-hydroxy quinone moiety. amicenomycin B3), vineomycin B24,5)and vineomycin C6), Fermentation on a 20-liter scale delivered sufficient where according to the investigations of IMAMURA et. al.7), material for the structure elucidation. the angular ring was opened and anthraquinones with substituted side chains at C-2 were resulting.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,428,163 Mills 45) Date of Patent: Jun
    US00542.8163A United States Patent (19) 11 Patent Number: 5,428,163 Mills 45) Date of Patent: Jun. 27, 1995 54 PRODRUGS FOR SELECTIVE DRUG Agarwal, R. P., etal, Biochem. Pharmacol., 26, 359-367 DELVERY (1977). 76 Inventor: Allen, R. C., Chemical and Biological Generation of Randell L. Mills, R.D. #2, Excited States, 309-345 (1968). Cochranville, Pa. 19330 Alston, T.A., etal, Biochemistry, 26, 4082-4085 (1987). 21 Appl. No.: 446,439 Ando, W., et al., Photochemistry and Photobiology, 30, 81-87 (1979). (22 Filed: Dec. 4, 1989 Arakawa, H., et al, Chem. Pharm. Bull, 30(8), 3036-3039 (1982). Related U.S. Application Data Asano, T., et al, Mol. Pharm., 13, 400-406 (1977). 63 Continuation-in-part of Ser. No. 948,326, Dec. 31, Baker, B. R., “Design of Active-Site-Directed Irrever 1986, abandoned. sible Enzyme Inhibitors', 9 (1975). Baker, B. R., et al, J. Med. Chem., 10, 682-685 (1967). 51) Int. Cl. .................. C07D 403/02; A61K 31/495 Baker, B.R., etal, J. Med. Chem., 10, 1101-1105 (1967). 52 U.S. C. .................................................... 544/232 Baker, B. R., et al, J.Med. Chem., 10, 1134-1138 (1967). 58) Field of Search ................ 534/573; 514/150, 151; Baker, B. R., et al, J. Med. Chem., 11, 666-672 (1968). 435/5, 6, 935/78; 544/232 Baldessarini, R. J., et al, Biochem. Pharmacology, 22, (56) References Cited 247-256 (1973). Baldwin, J. J., et al, J. Med. Chem., 18, 895-900 (1975). U.S. PATENT DOCUMENTS Beard, N.A., et al, Br. J. Pharmac., 54, 65-74 (1975).
    [Show full text]
  • Hitta Denna Unutrition Adult Clio
    HITTA DENNAUS UNUTRITION 20180042989A1 ADULT CLIO III ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0042989 A1 Aversa et al. ( 43 ) Pub . Date : Feb . 15 , 2018 ( 54 ) IMMUNOMODULATORY COMPOSITIONS Publication Classification (51 ) Int. Cl. ( 71 ) Applicant : Sigmoid Pharma Limited , Dublin ( IE ) A61K 38 / 13 ( 2006 .01 ) (72 ) Inventors : Vincenzo Aversa , Ridgewood Swords A61K 31 / 502 ( 2006 . 01) ( IE ) ; Ivan Coulter, Mount Merrion A61K 31/ 436 (2006 . 01 ) ( IE ) ; Mónica Torres Rosa , Dublin (IE ) ; A61K 45 / 06 ( 2006 .01 ) Bernard Francis McDonald , A61K 9 / 16 ( 2006 . 01 ) Castleblayney (IE ) A61K 9 /50 ( 2006 .01 ) (52 ) U . S . CI. ( 73) Assignee : Sigmoid Pharma Limited , Dublin ( IE ) CPC . .. .. .. A61K 38 / 13 ( 2013 .01 ) ; A6IK 9 / 167 (2013 .01 ) ; A61K 9 / 16 (2013 . 01 ) ; A61K 9 /5036 (21 ) Appl . No. : 15 /791 , 104 ( 2013 .01 ) ; A61K 31 / 436 ( 2013 .01 ) ; A61K 9 /5084 ( 2013 .01 ) ; A61K 9 / 1658 ( 2013 .01 ) ; (22 ) Filed : Oct . 23, 2017 A61K 45 / 06 ( 2013 .01 ) ; A61K 31/ 502 ( 2013 .01 ) ; A61K 9 / 5042 (2013 . 01 ) ; A61K Related U . S . Application Data 2300 / 00 (2013 .01 ) (63 ) Continuation of application No . 13 /989 , 372 , filed on May 23 , 2013 , now Pat . No . 9 ,821 ,024 , filed as ( 57 ) ABSTRACT application No. PCT /EP2011 /071088 on Nov . 25 , 2011. Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a Foreign Application Priority Data hydroxylase inhibitor and /or an immunosuppressant. Exem (30 ) plary formulations comprise hydralazine as a hydroxylase Nov . 25 , 2010 (GB ) . .. 1020032 .7 inhibitor and / or cyclosporin A as an immunosuppressant.
    [Show full text]
  • Chemical Compounds and Pharmaceutical Compositions
    Europaisches Patentamt (19) European Patent Office Office europeenpeen des brevets EP0414 730B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) intci.6: C12Q 1/68, C12Q 1/70, of the grant of the patent: C07C 245/00, G01 N 33/566, 15.12.1999 Bulletin 1999/50 A61 K 47/48 (21) Application number: 89904951.4 (86) International application number: PCT/US89/01361 (22) Date of filing: 31.03.1989 (87) International publication number: WO 89/09833 (19.10.1989 Gazette 1989/25) (54) Chemical Compounds and pharmaceutical compositions capable of releasing a drug Chemische Verbindungen und pharmazeutische Zusammensetzungen zur Freisetzung von Arzneimitteln Composes chimiques et compositions pharmaceutiques capables de delivrer un medicament (84) Designated Contracting States: (74) Representative: Beetz & Partner Patentanwalte AT BE CH DE FR GB IT LI LU NL SE Steinsdorfstrasse 10 80538 Miinchen (DE) (30) Priority: 31.03.1988 US 175970 (56) References cited: (43) Date of publication of application: WO-A-83/04255 US-A- 3 798 131 06.03.1991 Bulletin 1991/10 US-A- 4 599 303 US-A- 4 626 501 US-A- 4 656 127 US-A- 4 683 194 (73) Proprietor: Mills, Randell L. US-A- 4 716 106 Cochranville Pennsylvania 19330 (US) • STN FILE SERVER & FILE CA (KARLSRUHE) & (72) Inventor: Mills, Randell L. CHEMICAL ABSTRACTS, vol. 94, no. 9, 1980, Cochranville Pennsylvania 19330 (US) Columbus, Ohio, US; abstract no. 63484, ANNA D. INGLOT 'DEXTRAN T FRACTIONS SUBSTITUTED WITH CIBACRON BLUE F3G-A AS CARRIERS FOR MOUSE INTERFERON' DO o CO Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice the Patent Office of the Notice of shall be filed in o to European opposition to European patent granted.
    [Show full text]
  • Amino Acid Hydroxylase Inhibitors
    CHAPTER 2 Amino Acid Hydroxylase Inhibitors Edith G. McGeer and Patrick L. McGeer I. Introduction 45 II. Properties of the Enzymes 46 A. Tyrosine Hydroxylase 46 B. Tryptophan Hydroxylase 50 C. Phenylalanine Hydroxylase 54 III. In Vitro Inhibitors of the Hydroxylases 56 A. Catechols 57 B. Iron-Complexing Agents 63 C. Compounds Capable of Easy Oxidation/Reduction 63 D. Amino Acid Analogs 65 IV. In Vivo Inhibitors of the Hydroxylases 71 A. Catechols 71 B. Iron-Complexing Agents 73 C. Compounds Capable of Easy Oxidation/Reduction 74 D. Amino Acid Analogs 74 E. Miscellaneous in Vivo Inhibitors 83 V. Indirect Mechanisms of Inhibition 84 A. Direct Feedback (Product) Inhibition 84 B. Substrate Availability 85 C. Hormonal Influences 86 D. Indirect Feedback (Interneuronal) Inhibition 88 VI. Conclusion 89 References 90 I. INTRODUCTION There are three principal reactions occurring in animals which involve the introduction of a hydroxyl group into the aromatic ring of an amino acid. These reactions are the hydroxylations of tryptophan to 5-hydroxy- tryptophan (5-HTP), of phenylalanine to tyrosine, and of tyrosine to 3,4-dihydroxyphenylalanine (DOPA). There are certain similarities in 45 46 E. G. MCGEER AND P. L. MCGEER these reactions but important differences as well. An understanding of these similarities and differences is needed for an interpretation of the various actions of different types of inhibitors. In each hydroxylation molecular oxygen is required (1) as well as the same, or a highly similar, pteridine cofactor. The general reaction is presumed to be hydroxylase XH4 + ArH + 02 > ArOH + H20 + XH2 where X is a pteridine and ArH represents the amino acid substrate.
    [Show full text]
  • PAPERS of DR. W O Irlezawa 1. Stvdies on a Substance Inhibiting
    HETEROCYCLES, Vol 13, 1979 PAPERS OF DR. WOIRlEZAWA 1. Stvdies on a substance inhibiting Gram negative bacteria, produced by Penicillium. Isolation and crystallization of patulin-like substance. (in Japanese): H. Umezawa, K. Uekane, Y. Mizuhara and M. Hagiwara, Nihon Iji Shimpo, No. 1179, 68, 1946. 2. Studies on antibacterial substances produced by streptomyces. Isolation of streptomycin, streptothricin and actinomycin A. (in Japanese): H. Umezawa, M. Hayano, T. Takeuchi, B. To and Y. Mizuhara, Kagaku Ryoho Kenkyusho -, 1, 196, 1947. 3. Differentiation of coccus and bacillus by observation of schlieren streaks. (in Japanese): H. Umezmra and T. Takeuchi, Saikinaaku w,2, 33-34, 1947; Ni~pooIaaku. No. 3408, 174, 1946. 4. Assay of tuberculin. (in Japanese); H. Umezawa and F. Shiozawa, Saikingaku m, 2, 34-36, 1447; Nippon Igaku, No. 3402, 44, 1946. 5. A crystalline antibacterial substance from Penicillim leeucopus and four other strains of Penicillium sp. and Asperaillus and its probable identity with patulin. (in Japa- nese): H. Umeeawa, Y. Mizuhara, K. Uekane and M. Hagihara, J. Penicillin, 1, 6-13, 1947/8. 6. Studies on the penicillin. 11. Relation between the growth inhibitory effect and the protective activity &-. (in Japanese): H. Umeeawa and T. Takeuchi, J. Penicillin, 1, 14-18, 194718. 7. Studies on the increased resistance of Staphylococcus against penicillin, patulin, citrinin and toluquinone. (in Japanese): H. Umezawa and K. Uekane, J. Penicillin, 1, 79-81, 194718. 8. studies on the antibacterial substance from acrinomyces. I. A crystalline antibacterial sub- stance from a strain of actinomyces. (in Japanese); H. Umezawa, S. Hayano, T. Takeuchi and Y. Mizuhara, J.
    [Show full text]